PLoS ONE (Nov 2007)

Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action.

  • Esther Llagostera,
  • Daniele Catalucci,
  • Luc Marti,
  • Marc Liesa,
  • Marta Camps,
  • Theodore P Ciaraldi,
  • Richard Kondo,
  • Sita Reddy,
  • Wolfgang H Dillmann,
  • Manuel Palacin,
  • Antonio Zorzano,
  • Pilar Ruiz-Lozano,
  • Ramon Gomis,
  • Perla Kaliman

DOI
https://doi.org/10.1371/journal.pone.0001134
Journal volume & issue
Vol. 2, no. 11
p. e1134

Abstract

Read online

Myotonic dystrophy 1 (DM1) is caused by a CTG expansion in the 3'-unstranslated region of the DMPK gene, which encodes a serine/threonine protein kinase. One of the common clinical features of DM1 patients is insulin resistance, which has been associated with a pathogenic effect of the repeat expansions. Here we show that DMPK itself is a positive modulator of insulin action. DMPK-deficient (dmpk-/-) mice exhibit impaired insulin signaling in muscle tissues but not in adipocytes and liver, tissues in which DMPK is not expressed. Dmpk-/- mice display metabolic derangements such as abnormal glucose tolerance, reduced glucose uptake and impaired insulin-dependent GLUT4 trafficking in muscle. Using DMPK mutants, we show that DMPK is required for a correct intracellular trafficking of insulin and IGF-1 receptors, providing a mechanism to explain the molecular and metabolic phenotype of dmpk-/- mice. Taken together, these findings indicate that reduced DMPK expression may directly influence the onset of insulin-resistance in DM1 patients and point to dmpk as a new candidate gene for susceptibility to type 2-diabetes.